Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Carlo Buonerba Clear advanced filters

  • The exclusive expression of well-defined antigens renders prostate cancer an attractive target for immunotherapy. Di Lorenzoet al. review clinical results of immunotherapy trials in patients with prostate cancer and discuss methodological issues related to the evaluation of treatment efficacy of immunotherapeutic agents.

    • Giuseppe Di Lorenzo
    • Carlo Buonerba
    • Philip W. Kantoff
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 8, P: 551-561

  • Final results of the CALGB 90206 and AVOREN trials have failed to demonstrate an overall survival benefit for bevacizumab plus interferon compared to interferon monotherapy in patients with metastatic renal cell carcinoma. Progression-free survival or objective response rate might be more suitable primary end points in phase III trials.

    • Giuseppe Di Lorenzo
    • Carlo Buonerba
    News & Views
    Nature Reviews Urology
    Volume: 7, P: 367-368